ArticleAmerican journal of translational research2026
Tanshinone IIA prevents septicemia acute kidney injury via regulating the DUSP10/JNK/P38/NLRP3 pathway.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting integrated cell death networks in sepsis‑associated acute kidney injury: Shared regulatory nodes and diet‑related small molecule modulation (Review).International journal of molecular medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the protective effects and underlying mechanisms of tanshinone IIA in preventing septicemia acute kidney injury (SA-AKI).
methodsMice were pretreated with tanshinone IIA via intraperitoneal injection, followed by lipopolysaccharide (LPS) administration to induce SA-AKI. Hematoxylin-eosin (HE) staining was used to assess renal tissue injury to confirm successful model establishment. In vitro, HK2 cells were treated with LPS and/or tanshinone IIA. Differentially expressed genes (DEGs) between the LPS and tanshinone IIA + LPS groups were identified via high-throughput sequencing. qPCR was performed to validate mRNA expression of key DEGs. Protein expression in mouse kidney and HK2 cells was analyzed using immunohistochemistry and western blot.
resultsMice in the SA-AKI model demonstrated severe renal damage, with elevated levels of serum creatinine and urea nitrogen, as well as increased apoptosis and glycogen accumulation. Tanshinone IIA pretreatment significantly alleviated these pathological changes. Flow cytometry confirmed that LPS induced HK2 cell apoptosis, which was attenuated by tanshinone IIA. Transcriptomic analysis revealed 121 upregulated and 65 downregulated genes. Western blot showed that LPS increased JNK, p38, NLRP3 and Caspase-1 expression, and decreased DUSP10 and ALDH2 expression, while tanshinone IIA pretreatment reversed these effects. Similarly, immunohistochemistry and western blot analyses demonstrated elevated contents of KIM-1, NLRP3, JNK and Caspase-1, and reduced DUSP10 and ALDH2 in SA-AKI mice.
conclusionTanshinone IIA exerts a protective effect against SA-AKI by mitigating inflammation and apoptosis. Mechanistically, these effects appear to be mediated through DUSP10 and modulation of the JNK/P38/NLRP3 pathway. These findings suggest that tanshinone IIA might be a potential therapeutic strategy for SA-AKI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.